MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Hardy-Werbin, Max
• dc.contributor.author del Rey-Vergara, Raúl
• dc.contributor.author Galindo-Campos, Miguel A.
• dc.contributor.author Moliner Jiménez, Laura
• dc.contributor.author Arriola Aperribay, Edurne
• dc.date.accessioned 2019-11-22T08:52:43Z
• dc.date.available 2019-11-22T08:52:43Z
• dc.date.issued 2019
• dc.description.abstract Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Within the potentially interesting targets, the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway activation is associated with worse survival and chemoresistance in SCLC. Preclinical data suggest that the inhibition of the MET pathway can revert chemoresistance and prevent tumor growth. Recently, immunotherapy has shown modest but relevant activity in SCLC. Interestingly, MET modulation seems to be involved in increasing the efficacy of standard checkpoint inhibitors. Here, we review the preclinical and clinical data of MET inhibition in SCLC, and the role of this pathway in the immune response.
• dc.format.mimetype application/pdf
• dc.identifier.citation Hardy-Werbin M, Del Rey-Vergara R, Galindo-Campos MA, Moliner L, Arriola E. et al. MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside. Cancers (Basel). 2019 Sep 20;11(10). pii: E1404. DOI 10.3390/cancers11101404
• dc.identifier.doi http://dx.doi.org/10.3390/cancers11101404
• dc.identifier.issn 2072-6694
• dc.identifier.uri http://hdl.handle.net/10230/42929
• dc.language.iso eng
• dc.publisher MDPI
• dc.rights © Hardy-Werbin M, Del Rey-Vergara R, Galindo-Campos MA, Moliner L, Arriola E. et al. by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword HGF
• dc.subject.keyword MET
• dc.subject.keyword Immunotherapy
• dc.subject.keyword Small cell lung cancer
• dc.title MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion